{"generic":"Human Papillomavirus Recombinant Vaccine Quadrivalent (Types 6, 11, 16, 18)","drugs":["Gardasil","Human Papillomavirus Recombinant Vaccine Quadrivalent (Types 6, 11, 16, 18)"],"mono":{"0":{"id":"928560-s-0","title":"Generic Names","mono":"Human Papillomavirus Recombinant Vaccine Quadrivalent (Types 6, 11, 16, 18)"},"1":{"id":"928560-s-1","title":"Dosing and Indications","sub":{"0":{"id":"928560-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>usual dose:<\/b> 3 doses series, 0.5 mL IM at 0, 1 to 2, and 6 months<\/li><li><b>Adenocarcinoma in situ of cervix; Prophylaxis:<\/b> (women through 26 years) 0.5 mL IM for 3 doses at 0, 1 to 2, and 6 months, or at 0, 2, and 6 months<\/li><li><b>Anal cancer, Virus types 16 and 18; Prophylaxis:<\/b> (women, through 26 years) 0.5 mL IM for 3 doses at 0, 1 to 2, and 6 months, or at 0, 2, and 6 months<\/li><li><b>Anal cancer, Virus types 16 and 18; Prophylaxis:<\/b> (men, through 21 years, and 22 through 26 years with immunocompromising conditions, HIV infection, and men who have sex with men) 0.5 mL IM for 3 doses at 0, 1 to 2, and 6 months, or (through 26 years) 0.5 mL IM for 3 doses at 0, 2, and 6 months<\/li><li><b>Anal intraepithelial neoplasia, Grades 1, 2, and 3; Prophylaxis:<\/b> (women, through 26 years) 0.5 mL IM for 3 doses at 0, 1 to 2, and 6 months, or at 0, 2, and 6 months<\/li><li><b>Anal intraepithelial neoplasia, Grades 1, 2, and 3; Prophylaxis:<\/b> (men, through 21 years, and 22 through 26 years with immunocompromising conditions, HIV infection, and men who have sex with men) 0.5 mL IM for 3 doses at 0, 1 to 2, and 6 months or (through 26 years) 0.5 mL IM for 3 doses at 0, 2, and 6 months<\/li><li><b>Cervical cancer, Virus types 16 and 18; Prophylaxis:<\/b> (women through 26 years) 0.5 mL IM for 3 doses at 0, 1 to 2, and 6 months, or at 0, 2, and 6 months<\/li><li><b>Cervical intraepithelial neoplasia, Grade 1, 2, 3; Prophylaxis:<\/b> (women through 26 years) 0.5 mL IM for 3 doses at 0, 1 to 2, and 6 months, or at 0, 2, and 6 months<\/li><li><b>Genital warts, Virus types 6 and 11; Prophylaxis:<\/b> (women, through 26 years) 0.5 mL IM for 3 doses at 0, 1 to 2, and 6 months, or at 0, 2, and 6 months<\/li><li><b>Genital warts, Virus types 6 and 11; Prophylaxis:<\/b> (men, through 21 years, and 22 through 26 years with immunocompromising conditions, HIV infection, and men who have sex with men) 0.5 mL IM for 3 doses at 0, 1 to 2, and 6 months, or (through 26 years) 0.5 mL IM for 3 doses at 0, 2, and 6 months<\/li><li><b>Malignant tumor of vagina, Virus types 16 and 18; Prophylaxis:<\/b> (women through 26 years) 0.5 mL IM for 3 doses at 0, 1 to 2, and 6 months, or at 0, 2, and 6 months<\/li><li><b>Malignant tumor of vulva, Virus types 16 and 18; Prophylaxis:<\/b> (women through 26 years) 0.5 mL IM for 3 doses at 0, 1 to 2, and 6 months, or at 0, 2, and 6 months<\/li><li><b>Vaginal intraepithelial neoplasia, Grade 2 and 3; Prophylaxis:<\/b> (women through 26 years) 0.5 mL IM for 3 doses at 0, 1 to 2, and 6 months, or at 0, 2, and 6 months<\/li><li><b>Vulval intraepithelial neoplasia (VIN), Grade 2 and 3; Prophylaxis:<\/b> (women through 26 years) 0.5 mL IM for 3 doses at 0, 1 to 2, and 6 months, or at 0, 2, and 6 months<\/li><\/ul>"},"1":{"id":"928560-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>usual dose:<\/b> 3 doses series, 0.5 mL IM at 0, 1 to 2, and 6 months; minimum age for vaccination is 9 years<\/li><li><b>Adenocarcinoma in situ of cervix; Prophylaxis:<\/b> (girls 9 years or older) 0.5 mL IM for 3 doses at 0, 1 to 2, and 6 months, or at 0, 2, and 6 months<\/li><li><b>Anal cancer, Virus types 16 and 18; Prophylaxis:<\/b> (9 years or older) 0.5 mL IM for 3 doses at 0, 1 to 2, and 6 months, or at 0, 2, and 6 months<\/li><li><b>Anal intraepithelial neoplasia, Grades 1, 2, and 3; Prophylaxis:<\/b> (9 years or older) 0.5 mL IM for 3 doses at 0, 1 to 2, and 6 months, or at 0, 2, and 6 months<\/li><li><b>Cervical cancer, Virus types 16 and 18; Prophylaxis:<\/b> (girls 9 years or older) 0.5 mL IM for 3 doses at 0, 1 to 2, and 6 months, or at 0, 2, and 6 months<\/li><li><b>Cervical intraepithelial neoplasia, Grade 1, 2, 3; Prophylaxis:<\/b> (girls 9 years or older) 0.5 mL IM for 3 doses at 0, 1 to 2, and 6 months, or at 0, 2, and 6 months<\/li><li><b>Genital warts, Virus types 6 and 11; Prophylaxis:<\/b> (9 years or older) 0.5 mL IM for 3 doses at 0, 1 to 2, and 6 months, or at 0, 2, and 6 months<\/li><li><b>Malignant tumor of vagina, Virus types 16 and 18; Prophylaxis:<\/b> (girls 9 years or older) 0.5 mL IM for 3 doses at 0, 1 to 2, and 6 months, or at 0, 2, and 6 months<\/li><li><b>Malignant tumor of vulva, Virus types 16 and 18; Prophylaxis:<\/b> (girls 9 years or older) 0.5 mL IM for 3 doses at 0, 1 to 2, and 6 months, or at 0, 2, and 6 months<\/li><li><b>Vaginal intraepithelial neoplasia, Grade 2 and 3; Prophylaxis:<\/b> (girls 9 years or older) 0.5 mL IM for 3 doses at 0, 1 to 2, and 6 months, or at 0, 2, and 6 months<\/li><li><b>Vulval intraepithelial neoplasia (VIN), Grade 2 and 3; Prophylaxis:<\/b> (girls 9 years or older) 0.5 mL IM for 3 doses at 0, 1 to 2, and 6 months, or at 0, 2, and 6 months<\/li><\/ul>"},"3":{"id":"928560-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Adenocarcinoma in situ of cervix; Prophylaxis<\/li><li>Anal cancer, Virus types 16 and 18; Prophylaxis<\/li><li>Anal intraepithelial neoplasia, Grades 1, 2, and 3; Prophylaxis<\/li><li>Cervical cancer, Virus types 16 and 18; Prophylaxis<\/li><li>Cervical intraepithelial neoplasia, Grade 1, 2, 3; Prophylaxis<\/li><li>Genital warts, Virus types 6 and 11; Prophylaxis<\/li><li>Malignant tumor of vagina, Virus types 16 and 18; Prophylaxis<\/li><li>Malignant tumor of vulva, Virus types 16 and 18; Prophylaxis<\/li><li>Vaginal intraepithelial neoplasia, Grade 2 and 3; Prophylaxis<\/li><li>Vulval intraepithelial neoplasia (VIN), Grade 2 and 3; Prophylaxis<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Adenocarcinoma in situ of cervix, Due to nonvaccine HPV types; Prophylaxis<\/li><li>Cervical intraepithelial neoplasia, Grade 1, 2, and 3 due to nonvaccine human papillomavirus types; Prophylaxis<\/li><\/ul>"}}},"3":{"id":"928560-s-3","title":"Contraindications\/Warnings","sub":[{"id":"928560-s-3-9","title":"Contraindications","mono":"hypersensitivity, including severe allergic reactions to yeast or following previous administration of human papillomavirus recombinant quadrivalent vaccine <br\/>"},{"id":"928560-s-3-10","title":"Precautions","mono":"<ul><li>acute illness with or without fever, moderate or severe; defer vaccination unless the benefit of protection outweighs the risk of an adverse reaction<\/li><li>pregnancy; not recommended; if pregnancy occurs after starting vaccination series, delay remainder of series until pregnancy completed<\/li><li>syncope, sometimes associated with tonic-clonic movements and other seizure-like activity, has been reported; monitoring recommended<\/li><li>report suspected adverse events to Merck at 1-877-888-4231, or to the Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967 or www.vaers.hhs.gov<\/li><\/ul>"},{"id":"928560-s-3-11","title":"Pregnancy Category","mono":"B (FDA)<br\/>"},{"id":"928560-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"928560-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Erythema at injection site (16.7% to 24.7%), Injection site pain (61.5% to 83.9%), Injection site pruritus (3.2%), Swelling at injection site (13.9% to 25.4%)<\/li><li><b>Gastrointestinal:<\/b>Nausea (2% to 6.7%)<\/li><li><b>Neurologic:<\/b>Dizziness (1.2% to 4%), Headache (12.3% to 28.2%)<\/li><li><b>Other:<\/b>Fever (8.2% to 13%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Syncope, Venous thromboembolism<\/li><li><b>Gastrointestinal:<\/b>Appendicitis (0.03%), Pancreatitis<\/li><li><b>Immunologic:<\/b>Anaphylaxis<\/li><li><b>Neurologic:<\/b>Disseminated encephalomyelitis, acute, Guillain-Barr  syndrome, Motor neuron disease, Transverse myelopathy syndrome<\/li><li><b>Respiratory:<\/b>Asthma, Bronchospasm<\/li><\/ul>"},"6":{"id":"928560-s-6","title":"Drug Name Info","sub":[{"id":"928560-s-6-17","title":"US Trade Names","mono":"Gardasil<br\/>"},{"id":"928560-s-6-18","title":"Synonyms","mono":"Human Papillomavirus Recomb Vaccine Quadrivalent<br\/>"},{"id":"928560-s-6-19","title":"Class","mono":"Vaccine<br\/>"},{"id":"928560-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}]},"7":{"id":"928560-s-7","title":"Mechanism Of Action","mono":"development of humoral immune response against human papillomavirus types 6, 11, 16, and 18 <br\/>"},"9":{"id":"928560-s-9","title":"Administration","mono":"<b>Intramuscular<\/b><br\/><ul><li>administer in the deltoid region of the upper arm or in the higher anterolateral area of the thigh<\/li><li>do not inject intravascularly; subQ and intradermal administration have not been studied and therefore cannot be recommended<\/li><li>shake well before use; no dilution or reconstitution is necessary<\/li><li>may be administered concomitantly at the same visit, but at a different administration site, with the meningococcal vaccine (Menactra(R)); hepatitis B vaccine, recombinant (Recombivax HB(R)); or the reduced diphtheria toxoid, tetanus toxoid, and acellular pertussis vaccine, adsorbed (Adacel(R))<\/li><\/ul>"},"10":{"id":"928560-s-10","title":"Monitoring","mono":"<ul><li>development of human papillomavirus (HPV) antibodies<\/li><li>absence of clinical manifestations of human papillomavirus infection (ie, cervical intraepithelial  neoplasia, cervical cancer, cytological abnormalities)<\/li><li>signs of syncope, including tonic-clonic movements and other seizure-like activity, for 15 min after administration<\/li><\/ul>"},"13":{"id":"928560-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient that vaccine does not treat cancer (cervical, vulvar, vaginal, anal) or warts (anal, genital), and will not protect against other diseases caused by human papillomavirus.<\/li><li>Counsel female patient that cervical cancer screening is recommended after completed vaccine series.<\/li><li>Instruct patient to continue anal cancer screening if advised by physician.<\/li><li>Drug may cause nausea, dizziness, fever, pruritus, erythema, or swelling at injection site.<\/li><li>Inform patient that vaccine is given as 3 doses (0, 2, and 6 months) for complete vaccine series.<\/li><\/ul>"}}}